Table 2 Predicted Probabilities of Anti-Nucleocapsid Seroconversion Stratified by Sex and Comorbidity Status (Overall Across Full Follow-Up Period)

From: Anti-nucleocapsid and anti-spike antibody trajectories in people with post-covid condition versus acute-only infections: a nested longitudinal case-control study within the Virus Watch prospective cohort

 

Predicted Probability (95% CI)

 

PCC

Acute-Only

Sex

Female

82.3% (75.0%, 87.9%)

72.0% (66.0%, 77.3%)

Male

90.7% (79.6%, 96.1%)

80.2% (73.5%, 85.6%)

Comorbidities

Yes

81.0% (72.1%, 87.5%)

72.0% (64.1%, 78.8%)

No

88.9% (80.6%, 93.9%)

77.1% (71.7%, 81.8%)

Vaccination Status*

Unvaccinated

88.9% (80.1%, 94.1%)

72.0% (56.8%, 83.4%)

2 Doses

85.1% (78.9%, 89.8%)

77.6% (72.4%, 82.0%)

3 Doses

80.4% (65.8%, 89.8%)

82.3% (74.6%, 88.0%)

Variant*

Pre-Omicron

89.6% (81.8%, 94.3%)

74.3% (66.3%, 81.0%)

Omicron

75.6% (58.8%, 87.0%)

83.3% (74.6%, 89.4%)

  1. Note: 95% CI = 95% confidence interval; PCC = Post-Covid Condition
  2. * Mutually adjusted for vaccination status and variant of infection.
Back to article page